STIMULATE study: Statins influence on Minrin upregulation of von Willebrand factor and factor VIII

Conditions: Bloedstollingsstoornissen
Hemophilia A
Von Willebrand Disease

Registration Number: NL-OMON32666

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 20

Inclusion Criteria

1. Mild hemophilia A: defined as a F VIII deficiency with a F VIII plasma concentration of 10-40 IU mL-1, confirmed on at least two occasions.
2. or Von Willebrand disease type 1: defined as a VWF deficiency with a VWF plasma concentration of 10-40 IU mL-1, confirmed on at least two occasions.
3. DDAVP response has been tested at least once before, VWF activity and VWF antigen after DDAVP should not exceed > 200 %.
4. Age: 18 * 60 years
5. Male

Exclusion Criteria

1. Moderate/Severe hemophilia A: defined as a F VIII deficiency with a F VIII:C plasma concentration of * 2 IU mL-1, confirmed at at least two occasions.
2. Von Willebrand disease type 2 or 3
3. Clinical history of any other hemostatic or thrombotic disorder.
4. Clinical history of any disorder specified in Appendix C of the study protocol
5. Use of any medications specified in Appendix C of the study protocol
6. Medical indication for statin therapy.
7. Co-enrolment other clinical study
8. DDAVP response has not previously been tested or vWF antigen and vWF activity increase after previous DDAVP exposure was less than two fold.
9. First relative (brother/sister) participating in this study

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>* vWF antigen, vWF activity and vWF propeptide plasma levels after DDAVP<br /><br>stimulation, during statin therapy.<br /><br>* FVIII activity and F VIII antigen plasma levels after DDAVP stimulation,<br /><br>during statin therapy. </p><br>

Secondary Outcome Measures